RecruitingNCT06477484

Blood Biomarkers for Screening of Alzheimer's Disease

Blood-based Biomarkers for Early Alzheimer's Disease Screening

Sponsor

Peking University First Hospital

Enrollment

180 participants

Start Date

Jun 18, 2024

Study Type

OBSERVATIONAL

Conditions

Alzheimer s Disease Blood Biomarkers

Summary

The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are: * to identify core blood biomarker suitable for early screening of AD. * to establish a comprehensive model for the early identification of AD.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study examines whether certain proteins in the blood can be used to detect or predict Alzheimer's disease at an early stage, before significant symptoms appear. It is an observational blood-test study — no experimental treatment is given. **You may be eligible if...** - You are 50 years or older - You have been diagnosed with Alzheimer's disease or mild cognitive impairment (MCI), OR you are cognitively normal (participating as a comparison) - You are able to sign a consent form **You may NOT be eligible if...** - You have other conditions that can cause memory problems or confusion (such as severe depression, vitamin deficiencies, or other brain diseases) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.